Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.

Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F.

J Med Genet. 2004 Jun;41(6):474-80.

2.

Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.

Oros KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin PN.

Clin Genet. 2006 Oct;70(4):320-9.

PMID:
16965326
3.

Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models.

Roudgari H, Miedzybrodzka ZH, Haites NE.

Fam Cancer. 2008;7(3):199-212. Epub 2007 Dec 21.

PMID:
18097771
4.
5.

Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.

Evans DG, Young K, Bulman M, Shenton A, Wallace A, Lalloo F.

Clin Genet. 2008 Apr;73(4):338-45. doi: 10.1111/j.1399-0004.2008.00974.x. Epub 2008 Feb 26.

PMID:
18312450
6.

Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations.

Teller P, Hoskins KF, Zwaagstra A, Stanislaw C, Iyengar R, Green VL, Gabram SG.

Ann Surg Oncol. 2010 Jan;17(1):240-6. doi: 10.1245/s10434-009-0697-9. Epub 2009 Sep 18.

PMID:
19763692
7.

Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics.

de la Hoya M, Díez O, Pérez-Segura P, Godino J, Fernández JM, Sanz J, Alonso C, Baiget M, Díaz-Rubio E, Caldés T.

J Med Genet. 2003 Jul;40(7):503-10.

8.

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.

Antoniou AC, Durocher F, Smith P, Simard J, Easton DF; INHERIT BRCAs program members.

Breast Cancer Res. 2006;8(1):R3. Epub 2005 Dec 12.

9.

Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.

Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G.

J Natl Cancer Inst. 2002 Jun 5;94(11):844-51.

PMID:
12048272
10.

Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models.

Bodmer D, Ligtenberg MJ, van der Hout AH, Gloudemans S, Ansink K, Oosterwijk JC, Hoogerbrugge N.

Br J Cancer. 2006 Sep 18;95(6):757-62. Epub 2006 Aug 15.

11.

Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software.

Capalbo C, Ricevuto E, Vestri A, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G.

Eur J Hum Genet. 2006 Jan;14(1):49-54.

12.

Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.

Egeli U, Cecener G, Tunca B, Tasdelen I.

Cancer Invest. 2006 Aug-Sep;24(5):484-91.

PMID:
16939956
13.

Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.

Farshid G, Balleine RL, Cummings M, Waring P; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab).

Am J Surg Pathol. 2006 Nov;30(11):1357-66.

PMID:
17063074
14.

BRCA1 and BRCA2 mutations in a South American population.

Jara L, Ampuero S, Santibáñez E, Seccia L, Rodríguez J, Bustamante M, Martínez V, Catenaccio A, Lay-Son G, Blanco R, Reyes JM.

Cancer Genet Cytogenet. 2006 Apr 1;166(1):36-45.

PMID:
16616110
15.

Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.

Giannini G, Capalbo C, Ristori E, Ricevuto E, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A.

Breast Cancer Res Treat. 2006 Nov;100(1):83-91. Epub 2006 May 9.

PMID:
16847550
16.

Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.

James PA, Doherty R, Harris M, Mukesh BN, Milner A, Young MA, Scott C.

J Clin Oncol. 2006 Feb 1;24(4):707-15.

PMID:
16446345
17.

Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.

Rao NY, Hu Z, Yu JM, Li WF, Zhang B, Su FX, Wu J, Shen ZZ, Huang W, Shao ZM.

Breast Cancer Res Treat. 2009 Aug;116(3):563-70. doi: 10.1007/s10549-008-0181-4. Epub 2008 Sep 19.

PMID:
18807178
18.

[Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai].

Song CG, Hu Z, Yuan WT, Di GH, Shen ZZ, Huang W, Shao ZM.

Zhonghua Yi Xue Za Zhi. 2005 Nov 16;85(43):3030-4. Chinese.

PMID:
16324400
19.

Sensitivity of BRCA1/2 mutation testing in 466 breast/ovarian cancer families.

Evans DG, Bulman M, Young K, Gokhale D, Lalloo F.

J Med Genet. 2003 Sep;40(9):e107. No abstract available.

20.

Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients.

Rao NY, Hu Z, Li WF, Huang J, Ma ZL, Zhang B, Su FX, Zhou J, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Yuan WT, Shen ZZ, Huang W, Shao ZM.

Breast Cancer Res Treat. 2009 Feb;113(3):467-77. doi: 10.1007/s10549-008-9965-9. Epub 2008 Mar 16.

PMID:
18343994

Supplemental Content

Support Center